Sino Biopharmaceutical Ltd (Sino Biopharma), a subsidiary of Charoen Pokphand Group Co Ltd, develops, produces, and distributes biopharmaceutical products, medicines, and Chinese medicines. The company serves therapeutic areas such as oncology, liver diseases, respiratory diseases, and surgery/analgesia.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Sino Biopharma focuses on advancing hepatitis medicines, respiratory system medicines, oncology medicines and cardio-cerebral medicines. The company has co-operation with various domestic and overseas pharmaceutical institutes and enterprises. The company has research centers located in Beijing, Nanjing, Lianyungang, Qingdao, and Shanghai. In FY2024, the company spent CNY5,089.2 million on its R&D activities, which as a percentage of revenue stood at 17.6% and grew 15.6 YoY. As of the December 2024, the company’s R&D pipeline includes 36 innovative oncology drug candidates in or beyond clinical trials of which three are at the marketing application stage, eight are in Phase III, 11 are in Phase II, and 14 are in Phase I. Additionally, the company has 14 biosimilar or generic oncology drug candidates in or beyond clinical trials, with six at the marketing application stage, two in pivotal clinical trials, and five in bioequivalence (BE) trials. The company had filed for 1,069 new patent applications and received 349 patent invention approvals. As of December 2024, the company had accumulated 5,082 effective patents and patent applications and received 1,958 patent invention approvals.